SAVA Stock Recent News

Stocks often lose much of their value as a result of controversies. Cassava Sciences is facing a raft of serious allegations from numerous parties.

Cassava Sciences' stock is highly disputed due to conflicting opinions on the science behind its drug candidate, but outside research supports its apparent drug effect. Biomarkers show strong reductions in patients treated with simufilam, indicating potential efficacy in Alzheimer's disease. The reduction of NfL values over six months is similar to what led to the accelerated approval of Qalsody for ALS.

One of the big slogans favored by CNBC pundit Jim Cramer is, “There's always a bull market somewhere.” I believe that's true.

Big problems appear to be getting worse for Cassava Sciences (NASDAQ: SAVA ). The clinical-stage biotech company is a former favorite among retail investors.

Cassava Sciences (NASDAQ: SAVA ) stock was hit hard after the market close yesterday following the publication of a Science article that released the details on a report published by the City University of New York (CUNY). The report accused Cassava collaborator and CUNY faculty member Hoau-Yan Wang of scientific misconduct, including image manipulation.

Cassava Sciences Inc has denied data manipulation after a probe into conduct over its Alzheimer's drug research was leaked yesterday, sending its shares spiralling lower.   Shares of Cassav were down nearly 21% on Friday morning at $13.97.

Shares of biotech company Cassava Sciences Inc. were slammed in extended trading Thursday, after the publication Science reported that an investigation accused a neuroscientist who often collaborated with the company of “long-standing and egregious misconduct” in data management and record keeping that raised serious questions about his research.

Cassava Sciences Inc has denied data manipulation after a probe into conduct over its Alzheimer's drug research was leaked yesterday, sending its shares into a spiral.   The company's share price on NASDAQ dropped 29.30% on pre-market trades to a nadir of US$8.25 before settling by 20:00 local time, after closing at US$17.56 yesterday.

The Alzheimer's Disease space is highly volatile, with stock prices reacting to positive or negative data from other companies in the sector. Cassava Sciences, Inc. experienced a correction after initial gains, highlighting the need for caution in the Alzheimer's space. Concerns were raised about the validity of Cassava's phase 2 trial, including participant bias, dropout bias, and the lack of a p-value.

A rash of insider buying helped buoy the clinical-stage biotech's stock. Cassava said it had completed the enrollment of a phase 3 trial for an Alzheimer's disease drug.